Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
BOULDER, CO—Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.04 billion market cap biotech company, recently sold 12,500 shares of the company’s common stock. The transaction, which took place on March 19, 2025, was executed at a weighted average price of $20.606 per share, resulting in a total sale value of $257,575. According to InvestingPro analysis, the stock is currently trading slightly above its Fair Value.
The sale was conducted under a Rule 10b5-1 trading plan that Lyssikatos had adopted on November 15, 2024. Following this transaction, Lyssikatos holds 1,002,688 shares indirectly through The Lyssikatos Revocable Trust, for which he serves as trustee. InvestingPro data shows analysts maintain a strong buy consensus with price targets ranging from $33 to $42, significantly above current trading levels.
The reported sale was executed in multiple trades with prices ranging from $20.23 to $21.16. The weighted average price reflects the overall transaction value. The stock has shown resilience with a 15.84% return over the past year, despite being down 7.02% year-to-date. Get more detailed insights and access to 6 additional ProTips with an InvestingPro subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.